Briefing
TOMBOLA: atezolizumab at ctDNA relapse after radical cystectomy
Phase 2 study that starts atezolizumab when circulating tumor DNA becomes positive after radical cystectomy for muscle-invasive bladder cancer, before or alongside radiographic metastases.
- Design: Phase 2 · Active, not recruiting